2-But-3-enyldisulfanyl-N-[4-(3-chloro-4-fluoro-phenylamino)-quinazolin-6-yl]-acetamide

ID: ALA4783884

Chembl Id: CHEMBL4783884

PubChem CID: 162665339

Max Phase: Preclinical

Molecular Formula: C20H18ClFN4OS2

Molecular Weight: 448.98

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  C=CCCSSCC(=O)Nc1ccc2ncnc(Nc3ccc(F)c(Cl)c3)c2c1

Standard InChI:  InChI=1S/C20H18ClFN4OS2/c1-2-3-8-28-29-11-19(27)25-13-5-7-18-15(9-13)20(24-12-23-18)26-14-4-6-17(22)16(21)10-14/h2,4-7,9-10,12H,1,3,8,11H2,(H,25,27)(H,23,24,26)

Standard InChI Key:  NTWHDNBIISUYIF-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA4783884

    ---

Associated Targets(Human)

EGFR Tclin Epidermal growth factor receptor erbB1 (33727 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Egfr Epidermal growth factor receptor erbB1 (106 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 448.98Molecular Weight (Monoisotopic): 448.0595AlogP: 6.06#Rotatable Bonds: 9
Polar Surface Area: 66.91Molecular Species: NEUTRALHBA: 6HBD: 2
#RO5 Violations: 1HBA (Lipinski): 5HBD (Lipinski): 2#RO5 Violations (Lipinski): 1
CX Acidic pKa: 13.46CX Basic pKa: 3.99CX LogP: 5.41CX LogD: 5.41
Aromatic Rings: 3Heavy Atoms: 29QED Weighted: 0.24Np Likeness Score: -1.63

References

1. Zheng YG,Zhang WQ,Meng L,Wu XQ,Zhang L,An L,Li CL,Gao CY,Xu L,Liu Y.  (2020)  Design, synthesis and biological evaluation of 4-aniline quinazoline derivatives conjugated with hydrogen sulfide (HS) donors as potent EGFR inhibitors against L858R resistance mutation.,  202  [PMID:32619886] [10.1016/j.ejmech.2020.112522]

Source